Dr. Erin Ellis is the lead investigator for the following clinical trials currently available at the Swedish Cancer Institute:
I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)
A Randomized Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
WI Bensinger, KS Schiffman, L Holmberg, FR Appelbaum, R Maziarz, P Montgomery, E Elllis, S Rivkin, P Weiden, et al. High-dose busulfan, melphalan, thiotepa, and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplanation, 1997.
Golom HM and Ellis E. Treatment options for hairy cell leukemia. Seminars in Oncology, 18: 7-11, 1991.
Ellis ED, Williams, SF and Golomb HM. Current advances and guidelines in therapy. In benign and malignant lymphadenopathies: A Guide to Clinical and Laboratory Diagosis, edited by GA Pangalis and A Polliak.
Moormeier JA, Williams SF, Kaminer LS, Ellis ED, Garner M, Farah, Weichselbaum RR, and Bitran JD. Autologous bone marrow transplantation followed by involved field radiotherapy in aptients with relapsed or refractory Hodgkin’s disease. Leukemia and Lymphoma.
Ellis ED, Williams, SF, moormeier JA, Mainer LS, and Bitran JD. A phase I-II study of high dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies. Bone Marrow Transplatnation, 6: 439-442, 1990.
Ellis ED, Moormeier JA and Golomb HM. The treatment of hairy cell leukemia; a review. Leukemia and Lymphoma, 1: 77-85, 1990.
Le Beau MM, Bitter MA, Larson RA, Doane LA, Ellis ED, Franklin WA, Rubin CM, Kadin ME and Varidman JW. The t(2;5)(p23;q35): A recurring chromosomal abnormality in Ki-1 positive anaplastic large cell lymphoma. Leukemia, 3: 866-870, 1989.
Ellis E, Vokes E, Hoffman P, Krishnasamy S, Gradishar W, English C, Ferguson M, Haraf D, Bitran J and Golomb H. A phase II study of neoadjuvant chemotherapy and concomitant chemoradiotherapy for stage III lung cancer. Proceedings of ASCO, 1991.
Bitran JD, Vokes EE, Hoffman PC, Ellis ED, Gradishar W and Golomb HM. Combines modality therapy for stage III non-small cell lung cancer (NSCLC). Third International Congress on Neoadjuvant Chemotherapy, February 6-9, 1991.
Ellis ED, Williams SF, Moormeier JA, Bitran JD and Ratain MJ. A phase I study of high dose amonafide with autologous bone marrow rescue (ABMR). American Federation for Clinical Research, Midwest Section, November 1, 1990.
Ellis E, Moormeier J, Williams S, Kaminer L, Mick R, Bitran J. A phase II study of mitoxantrone, vincristine, and 5-fluorouracil with leucovorin (MVFL) as induction chemotherapy in women with stage IV breast cancer. 13th Annual San Antonio Breast Cancer Symposium, November 2-3, 1990.
Ellis E, Moormeier J, Kaminer L, Mick R, Williams S and Bitran J. A phase I-II study of high dose cyclophosphamide, thiotepa and mitoxantrone (CTM) in autologous bone marrow reinfusion (ABMR) in patients with refractory malignancies. Proceedings of ASCO, 9: 17, 1990.
The Patient Rating score is based on responses given during the CAHPS Patient Experience Survey.Responses are measured on a 10 - point scale, with 10 being the best score. These scores are then translated to a 5 - point scale in order to display results in a 5 - star rating.Comments are also gathered from the same survey and displayed in their entirety with the exception of any language that may be considered slander, libel or contain private health information, which will be removed prior to publishing the comments.